###begin article-title 0
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2:</italic>
Linkage Disequilibrium Mapping of CHEK2: Common Variation and Breast Cancer Risk 
###end article-title 0
###begin p 1
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist. 
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 284 292 284 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 450 455 450 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Checkpoint kinase 2 (CHEK2) averts cancer development by promoting cell cycle arrest and activating DNA repair in genetically damaged cells. Previous investigation has established a role for the CHEK2 gene in breast cancer aetiology, but studies have largely been limited to the rare 1100delC mutation. Whether common polymorphisms in this gene influence breast cancer risk remains unknown. In this study, we aimed to assess the importance of common CHEK2 variants on population risk for breast cancer by capturing the majority of diversity in the gene using haplotype tagging single nucleotide polymorphisms (tagSNPs). 
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 531 539 531 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 789 797 789 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 86 91 <span type="species:ncbi:9606">women</span>
We analyzed 14 common SNPs spanning 52 kilobases (kb) of the CHEK2 gene in 92 Swedish women. Coverage evaluation indicated that these typed SNPs would efficiently convey association signal also from untyped SNPs in the same region. Six of the 14 SNPs predicted well both the haplotypic and single SNP variations within CHEK2. We genotyped these six tagSNPs in 1,577 postmenopausal breast cancer cases and 1,513 population controls, but found no convincing association between any common CHEK2 haplotype and breast cancer risk. The 1100delC mutation was rare in our Swedish population-0.7% in cases and 0.4% in controls-with a corresponding odds ratio for carriers versus noncarriers of 2.26 (95% confidence interval, 0.99-5.15). Estimates of the population frequency and the odds ratio of 1100delC indicate that our sample is representative of a Northern European population. 
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Notwithstanding the involvement of the CHEK2 gene in breast cancer aetiology, we show that common polymorphisms do not influence postmenopausal breast cancer risk. 
###end p 7
###begin p 8
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 104 109 <span type="species:ncbi:9606">women</span>
Rare mutations in the CHEK2 gene are involved in familial breast cancer. This large study among Swedish women did not find an association between common CHEK2 variants and breast cancer. 
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 69 70 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b001">1</xref>
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b002">2</xref>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b003">3</xref>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 312 318 312 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2,</italic>
###xml 614 615 614 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b004">4</xref>
###xml 51 56 <span type="species:ncbi:9606">women</span>
###xml 467 472 <span type="species:ncbi:9606">women</span>
Breast cancer is overall the most common cancer in women worldwide [ 1]. Twin and family studies have clearly demonstrated the importance of genetic contribution to breast cancer risk [ 2, 3]. Genetic studies of familial breast cancer have identified several high-penetrance mutations in genes such as BRCA1 and BRCA2, but these mutations contribute little to risk at the population level due to their low prevalence. Whilst genetic risk factors for breast cancer in women not carrying any high-penetrance mutations are largely unknown, a polygenic model has been suggested to account for residual familial risk [ 4], which anticipates small effects of low-penetrance genetic risk variants in combination with environmental influence. 
###end p 10
###begin p 11
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2,</italic>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b005">5</xref>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b008">8</xref>
###xml 443 444 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b009">9</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b010">10</xref>
CHEK2, encoding a cell-cycle checkpoint kinase, is a strong candidate gene for cancer susceptibility. Following phosphorylation of CHEK2 by ATM after DNA damage, the activated CHEK2 protein phosphorylates p53, Cdc25, and BRCA1, thereby arresting the cell cycle and activating DNA repair [ 5- 8]. As recently verified, the cellular surveillance system for DNA damage-checking and repair plays an important role in averting cancer development [ 9, 10]. 
###end p 11
###begin p 12
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 34 42 34 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b011">11</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b012">12</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b013">13</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b014">14</xref>
###xml 415 423 415 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b012">12</xref>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b015">15</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b023">23</xref>
###xml 569 577 569 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b024">24</xref>
###xml 811 816 811 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 818 826 818 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b025">25</xref>
###xml 961 966 961 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1007 1016 1007 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IVS2+1G-A</italic>
###xml 1021 1027 1021 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I157T,</italic>
###xml 1172 1174 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b015">15</xref>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b023">23</xref>
###xml 1180 1182 1180 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b026">26</xref>
###xml 1184 1186 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b027">27</xref>
###xml 1214 1216 1214 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b016">16</xref>
###xml 1218 1220 1218 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b028">28</xref>
###xml 1222 1224 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b029">29</xref>
###xml 1380 1385 1380 1385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1465 1467 1465 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b030">30</xref>
###xml 1503 1508 1503 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 867 872 <span type="species:ncbi:9606">women</span>
An association between the CHEK2* 1100delC variant and breast cancer risk was initially established in breast cancer families without BRCA1 or BRCA2 mutations [ 11, 12]. This deletion, first detected in a breast cancer case with a family history of the Li-Fraumeni syndrome [ 13], leads to a premature termination of translation that abolishes CHEK2 kinase activity [ 14]. Most subsequent population studies of the 1100delC mutation included few carriers and found no significant association with breast cancer risk [ 12, 15- 23]. Recently, the association between the 1100delC and breast cancer susceptibility was convincingly replicated in a pooled analysis of 10,860 unselected cases and 9,065 controls from ten studies in five countries [ 24]. In addition, a more recent study has further demonstrated that CHEK2* 1100delC confers an even higher lifetime risk in women with a family history of bilateral breast cancer [ 25]. Two other putatively functional CHEK2 single nucleotide polymorphisms (SNPs), IVS2+1G-A and I157T, have been studied in relation to breast cancer risk. Some groups have found an increased risk of breast cancer associated with these variants [ 15, 23, 26, 27], whilst others have not [ 16, 28, 29]. These polymorphisms are rare and could only make a limited contribution to the genetic risk for breast cancer at the population level. Of the two common CHEK2 polymorphisms studied so far, neither was associated with breast cancer risk [ 30]. Thus, whether common variants in CHEK2 are involved in breast cancer aetiology remains unknown. 
###end p 12
###begin p 13
###xml 87 92 87 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 264 269 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 389 397 389 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
To address this question, we analyzed the association between common haplotypes in the CHEK2 gene and breast cancer risk in a well-defined Swedish population consisting of 1,577 breast cancer cases and 1,513 controls. In addition, we explored interactions between CHEK2 variation and hormone-related risk factors for breast cancer. For comparison with other populations, we also genotyped 1100delC in the entire set of cases and controls. 
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Study Population
###end title 15
###begin p 16
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b031">31</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b035">35</xref>
###xml 168 173 <span type="species:ncbi:9606">women</span>
This study builds on an earlier population-based Swedish case-control study of postmenopausal breast cancer [ 31- 35], with a study base consisting of all Swedish-born women between 50 and 74 years of age that were resident in Sweden between October 1993 and March 1995. During that period, we identified all breast cancer cases at diagnosis through the six regional cancer registries in Sweden, to which reporting of all malignant tumours is mandatory. We randomly selected controls from the Swedish Registry of Total Population that matched the cases in 5-y age strata. Of the eligible cases (3,979) and controls (4,188), 3,345 (84%) cases and 3,454 (82%) controls participated in the initial questionnaire-based study providing detailed information about menopausal hormone use, reproductive history, and other lifestyle factors. 
###end p 16
###begin p 17
###xml 124 136 <span type="species:ncbi:9606">participants</span>
From this initial study, we randomly selected 1,500 cases and 1,500 age-frequency matched controls among the postmenopausal participants without any previous malignancy (except carcinoma in situ of the cervix or nonmelanoma skin cancer). With the intention of increasing statistical power in subgroup analyses, we further selected all remaining cases and controls (191 cases and 108 controls) who had used menopausal hormones (oestrogen only or any combination of oestrogen and progestin) for at least 4 y, and all (110 cases and 104 controls) with self-reported diabetes mellitus. Additionally, 345 controls that were shared between the initial breast cancer study and an endometrial cancer study with same inclusion criteria were added to our control sample. In total, we selected 1,828 cases and 2,057 controls.
###end p 17
###begin p 18
###xml 33 45 <span type="species:ncbi:9606">participants</span>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
Upon providing informed consent, participants donated whole blood. We collected archived paraffin-embedded, non-cancerous tissue samples for deceased breast cancer cases as well as for those breast cancer cases that declined to donate blood but consented to our use of the tissue. We obtained blood samples and archived tissue samples for 1,321 and 275 breast cancer patients, respectively, and blood samples from 1,524 controls. Reasons for nonparticipation included a lack of interest in research or a negative attitude towards genetic research, old age, and severe disease or death. For deceased cases and cases that consented to our access to tissue, the major reason for nonparticipation was unwillingness or lack of time at the respective pathology departments to retrieve the tissue. Population-based participation rates (taking into account the proportion that did not participate in the questionnaire study) for cases and controls were 73% and 61%, respectively.
###end p 18
###begin p 19
This study was approved by the Institutional Review Boards in Sweden and at the National University of Singapore.
###end p 19
###begin title 20
DNA Isolation
###end title 20
###begin p 21
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b036">36</xref>
###xml 433 441 <span type="species:ncbi:9606">patients</span>
DNA was extracted by the Swegene laboratories in Malmo (Sweden) from 4 ml of whole blood using the QIAamp DNA Blood Maxi Kit (Qiagen, Valencia, California, United States) according to the manufacturer's instructions. From nonmalignant cells in paraffin-embedded tissue, we extracted DNA using a standard phenol/chloroform/isoamyl alcohol protocol [ 36]. We successfully isolated DNA from 1,318 (blood) and 272 (tissue) breast cancer patients, and from 1,518 controls. 
###end p 21
###begin title 22
SNP Markers and Genotyping
###end title 22
###begin p 23
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
We selected SNPs in the CHEK2 gene and its 5-kb flanking sequences from dbSNP (build 123, ) and Celera databases, aiming for an initial marker density of at least one SNP per 5 kb. SNPs were genotyped using the Sequenom primer extension-based assay (San Diego, California, United States) following the manufacturer's instructions. Briefly, multiplex primer extension assays were designed with the SpectroDesigner software. As template, 5 ng of genomic DNA was used in a multiplex PCR reaction. The PCR product was further purified before the primer extension reaction to generate allele-specific base extension products. The base-extension products were detected in the MassARRAY time-of-flight mass spectrometry (MALDI-TOF) system (Sequenom) to determine genotypes. All genotyping results were generated and checked by laboratory staff unaware of case-control status. Only SNPs for which more than 85% of the samples gave a genotype call were used in further analyses. We genotyped 200 randomly selected SNPs in the 92 control samples using both the Sequenom system and the BeadArray system from Illumina (San Diego, California, United States). The genotype concordance was over 99.5%, suggesting high genotyping accuracy. 
###end p 23
###begin title 24
Linkage Disequilibrium Characterization and TagSNP Selection
###end title 24
###begin p 25
###xml 80 81 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b037">37</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b038">38</xref>
###xml 240 247 240 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tagSNPs</italic>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b039">39</xref>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 298 299 298 299 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 299 300 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 315 316 315 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 316 317 316 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 547 548 547 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 548 549 548 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 549 550 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b040">40</xref>
###xml 661 667 661 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2,</italic>
###xml 766 768 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b041">41</xref>
###xml 940 941 940 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 941 942 941 942 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 958 960 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b042">42</xref>
###xml 1276 1278 1276 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b043">43</xref>
To characterize the linkage disequilibrium (LD) pattern, we calculated pairwise D' and R2 values using two-SNP haplotypes inferred via the EH plus program [ 37]. We reconstructed haplotypes using the PLEM algorithm [ 38] implemented in the tagSNPs program [ 39], and selected tagSNPs based on the Rh2 coefficient. Rh2 is the squared correlation between true haplotype dosage (number of copies of a haplotype) and the haplotype dosage predicted by tagSNPs. We chose tagSNPs so that common SNP genotypes and common haplotypes were predicted with an Rh2 value of 0.8 or higher [ 40]. In order to evaluate our tagSNP performance in capturing unobserved SNPs within CHEK2, and to assess whether we needed a denser set of markers, we performed the SNP-dropping analysis [ 41]. In brief, each of the 14 genotyped SNPs was dropped in turn, and tagSNPs were selected from the remaining 13 SNPs so that their haplotypes predicted the 13 SNPs with an R2 value of 0.9 [ 42]. A slightly more stringent value of 0.9 was used here, as we were predicting only SNPs and not haplotypes with our tagSNPs. We then estimated how well the tagSNP haplotypes of the remaining 13 SNPs predicted the dropped SNP, an evaluation that can provide an unbiased and accurate estimate of tagSNP performance [ 43]. This method assumes the markers to be a random selection of the polymorphisms in the gene. However, some intervals between adjacent genotyped SNPs exceeded 5 kb. We therefore employed additional tests for these intervals. If the tagSNPs selected using only the set of SNPs on one side of the interval predicted the individual SNPs on the other side sufficiently well, then we judged the coverage to be adequate. We had five intervals greater than 5 kb, thus ten sets of predictions. One of these ten was ignored, as there were only two SNPs to the left of the gap. 
###end p 25
###begin title 26
Statistical Analyses
###end title 26
###begin p 27
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b044">44</xref>
###xml 1293 1295 1289 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b039">39</xref>
###xml 1312 1313 1308 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1313 1314 1309 1310 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 1314 1315 1310 1311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1535 1537 1531 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b045">45</xref>
###xml 1628 1635 1624 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t001">Table 1</xref>
###xml 1680 1685 1676 1681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1784 1789 1780 1785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 2197 2199 2193 2195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b046">46</xref>
We first conducted the haplotype-based association analysis, since the tagSNPs were chosen primarily such that their haplotypes can accurately predict common SNPs in the gene. Our testing strategy was to first fit a single model and to assess for each stratum the haplotype-trait association as a global likelihood ratio test (on 7 degrees of freedom). The global test corresponds to carrying out seven tests on 1 degree of freedom each, and applying a correction for multiple hypothesis testing. Only if the global test was significant did we proceed to testing individual haplotype contrasts, adjusting for multiple testing [ 44]. We first computed expected haplotype dosage using haplotype frequencies estimated for cases and controls combined, assuming Hardy-Weinberg equilibrium (HWE). We then included the haplotype dosage as a covariate in a logistic regression model conditioned on the variables used for sampling: age (5-y age groups), menopausal oestrogen only use (never, < 4 y, or >/= 4 y), menopausal oestrogen and progestin use (never, < 4 y, or >/= 4 y) and self-reported diabetes mellitus (yes or no). The appropriateness of the approach, which in imputing haplotypes does not condition on disease status and the nonrandom ascertainment scheme, is argued for by Stram et al. [ 39]. That is, when Rh2 values are high, as is the case here, point and interval estimates obtained by this approach will be reasonably accurate. Confounding has been defined as the presence of a common cause to the exposure and the outcome [ 45], and we believe that the lifestyle and reproductive breast cancer risk factors, shown in Table 1, are unlikely to cause genetic variation in CHEK2. However, to assess whether the risk factors could be intermediates in the causal pathway between CHEK2 and breast cancer, we tested whether there was an association between the tagSNPs and any of the risk factors among the randomly sampled controls using a Kruskal-Wallis test. We also assessed the associations between groups of haplotypes and breast cancer risk. Since there is no biological reason to cluster haplotypes on the basis of their frequency, we employed a Bayesian association mapping approach [ 46] that clusters haplotypes according to their allelic similarity. 
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
Study Population
###end title 29
###begin p 30
###xml 127 134 127 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t001">Table 1</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b047">47</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b048">48</xref>
###xml 32 44 <span type="species:ncbi:9606">participants</span>
Selected characteristics of the participants in the parent questionnaire study and the current genetic study are summarized in Table 1. The distribution of nongenetic factors among cases and controls in the current study were comparable to those in the parent study and reflected established associations [ 47, 48]. The exceptions were long-term menopausal hormone use and diabetes mellitus, which had been consciously oversampled into the current study. 
###end p 30
###begin p 31
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Cases who donated a tissue sample were on average 1.5 y older and were more likely to have been diagnosed with stage 2 or more advanced cancers ( p < 0.0001) compared to cases who donated a blood sample. However, no significant differences in genotype frequencies were evident between cases who participated via blood or tissue samples (unpublished data). Furthermore, genotype frequencies were similar between tumours cm or smaller in diameter without lymph node involvement and tumours larger than 2 cm or with spread to regional lymph nodes (unpublished data). 
###end p 31
###begin title 32
LD Pattern and Coverage Estimation
###end title 32
###begin p 33
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2,</italic>
###xml 66 74 66 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030168-g001">Figure 1</xref>
###xml 79 86 79 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t002">Table 2</xref>
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 285 290 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b049">49</xref>
###xml 545 550 545 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 694 702 694 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030168-g001">Figure 1</xref>
###xml 731 736 731 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1070 1077 1070 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t003">Table 3</xref>
###xml 1130 1138 1130 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030168-g001">Figure 1</xref>
###xml 1143 1150 1143 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t002">Table 2</xref>
###xml 1267 1272 1267 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1289 1290 1289 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1290 1291 1290 1291 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 1291 1292 1291 1292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Of 34 successfully genotyped SNPs in CHEK2, 23 were polymorphic ( Figure 1 and Table 2), but five of them showed a significant deviation ( p < 0.01) from HWE and were therefore excluded from further analyses. The five problematic SNPs were all located within the shared region between CHEK2 and several homologous pseudogenes [ 49]. Of the remaining 18 polymorphic SNPs, 14 were common (here defined as having a minor allele frequency [MAF] of at least 0.03) and were therefore used to characterize the LD pattern and haplotype structure within CHEK2. The 14 SNPs spanned 52 kb of the gene, which yielded a mean and median density of one SNP per 4 kb and 3.2 kb, respectively. The D' pattern ( Figure 1) suggested strong LD across CHEK2 without extensive recombination, and we therefore treated the whole gene as a single haplotype block in our subsequent haplotype reconstruction. We identified a total of 31 haplotypes from the 14 SNPs, six of which were common (i.e., had an estimated population frequency of at least 0.03) and accounted for 81% of the chromosomes ( Table 3). We selected six tagSNPs from the 14 common SNPs ( Figure 1 and Table 2) that could efficiently and accurately predict the eight remaining common SNPs and the six common haplotypes within CHEK2 with an average Rh2 of 0.94. 
###end p 33
###begin p 34
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 74 81 74 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t002">Table 2</xref>
###xml 144 152 144 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
Four of the 34 typed CHEK2 SNPs were nonsynonymous coding polymorphisms ( Table 2). None of these polymorphisms were common and, except for the 1100delC mutation, were not analyzed further. 
###end p 34
###begin p 35
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b050">50</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b041">41</xref>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 235 236 235 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 293 294 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 443 448 443 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Since one cannot assume that tagSNPs capture nongenotyped SNPs as efficiently as genotyped SNPs [ 50], we used the SNP dropping method [ 41] to evaluate tagSNP performance. We found that the dropped SNPs were captured with an average R2 of 0.93, with 13 of the 14 dropped SNPs (93%) having an R2 greater than 0.75. Therefore, the six selected tagSNPs could efficiently capture not only all the genotyped but also unobserved common SNPs within CHEK2. Some intervals between adjacent SNPs exceeded 5 kb. We found the average proportion of the variance on one side of the intervals captured by tagSNPs chosen from the other side was at least 0.68 and averaged 0.75. This is likely to be an underestimate, as the markers considered were a much greater distance apart than the polymorphisms in the intervals of interest. Thus we consider such gaps to present little problem and conclude that our gene is sufficiently densely genotyped and that our tagSNPs effectively capture the common variation present in the gene. 
###end p 35
###begin title 36
Association Analyses
###end title 36
###begin p 37
###xml 324 331 324 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t001">Table 1</xref>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAG2</italic>
###xml 342 346 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAG4</italic>
###xml 391 392 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 497 504 497 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAG2, p</italic>
###xml 514 521 514 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAG4, p</italic>
We successfully genotyped the six tagSNPs in 1,577 breast cancer cases and 1,513 controls. All six tagSNPs were in HWE among the controls (unpublished data). We assessed, among the randomly selected controls, whether any of the tagSNPs were associated with the lifestyle and reproductive breast cancer risk factors shown in Table 1. TAG2 and TAG4 were statistically associated with parity ( p = 0.029 and p = 0.009, respectively), which showed a statistically significant trend for allelic dose ( TAG2, p = 0.006; TAG4, p = 0.0002). 
###end p 37
###begin p 38
###xml 24 32 24 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="st001">Table S1</xref>
###xml 85 92 85 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t004">Table 4</xref>
###xml 489 490 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 500 507 500 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t004">Table 4</xref>
###xml 1012 1020 1012 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 1032 1033 1032 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1430 1431 1430 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1493 1501 1493 1501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="st002">Table S2</xref>
We identified 19 rare ( Table S1) and seven common haplotypes from the six tagSNPs ( Table 4). The 19 rare haplotypes were collapsed into a single group in the association analyses. One additional common haplotype was identified in the full set of controls, which was not identified in the preliminary 92 controls. A global test of association, including all common haplotypes and the 19 rare haplotypes as one group in the model, was not statistically significant (likelihood ratio test, p = 0.19). Table 4 presents odds ratios (ORs) and confidence intervals (CIs) for tagSNP haplotypes using the most common haplotype (haplotype 1) as reference. None of the common haplotypes increased the risk of breast cancer, but the comparison between the group of 19 rare haplotypes against the reference showed a slight association with breast cancer risk (OR 1.24; 95% CI, 1.02-1.51), which did not, however, carry over to the global test, in which multiple testing has been formally accounted for. After excluding the 1100delC carriers ( n = 28) from the analysis, this association decreased (OR 1.20; 95% CI, 0.98-1.47), whilst the odds ratios for the common haplotypes remained unchanged. Comparing carriers to noncarriers of each haplotype, instead of using haplotype 1 as reference, did not substantially affect the results (unpublished data). Considering only breast cancer cases eventually diagnosed with a second breast cancer ( n = 72) similarly did not provide any convincing association ( Table S2). These findings remained unaltered after restricting the analyses to the randomly selected cases and controls or after including other breast cancer risk factors, including parity, as covariates in the logistic regression models. 
###end p 38
###begin p 39
###xml 179 188 179 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="st003">Tables S3</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="st007">S7</xref>
We stratified the haplotype analysis by several breast cancer risk factors: first-degree family history, body mass index, age at first birth, menopausal hormone use, and parity ( Tables S3- S7, respectively). None of the stratified analyses yielded a significant (alpha = 0.05) global test of association. 
###end p 39
###begin p 40
The 19 rare haplotypes accounted for approximately 20% of the chromosomes. Clustering haplotypes based on their allelic similarity did not provide an indication of a disease susceptibility locus in the region.
###end p 40
###begin p 41
###xml 90 98 90 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="st008">Table S8</xref>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAG2</italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAG4,</italic>
We also tested the association between tagSNP genotypes and breast cancer risk, overall ( Table S8) and stratified by other risk factors (unpublished data), but no additional compelling results emerged. Adjusting the models including TAG2 or TAG4, for parity did not change our results. 
###end p 41
###begin title 42
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 19 27 19 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
Analysis of CHEK2* 1100delC
###end title 42
###begin p 43
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 372 379 372 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t005">Table 5</xref>
###xml 386 394 386 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 561 568 561 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030168-t004">Table 4</xref>
The 1100delC mutation, genotyped in 1,510 cases and 1,334 controls, was rare in our Swedish population, with a frequency of 0.4% in the controls (HWE, p = 0.89). The deletion was slightly more common in the cases (0.7%) than in the controls, and the corresponding age- and sampling scheme-adjusted odds ratio for carriers versus noncarriers was 2.26 (95% CI, 0.99-5.15) ( Table 5). The 1100delC was exclusively carried on rare haplotypes, which may explain the marginally significant association between the group of 19 rare haplotypes and breast cancer risk ( Table 4). 
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 169 177 169 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
Our extensive linkage disequilibrium mapping association study did not provide support for an association between common variations in CHEK2 and breast cancer risk. The 1100delC mutation was more common in cases than in controls in our study population, but the difference was not statistically significant. The genotype frequencies were similar to those reported in other populations, thus confirming that our study population is representative of other Northern European populations. 
###end p 45
###begin p 46
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 458 463 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b017">17</xref>
###xml 745 750 745 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b042">42</xref>
###xml 1003 1004 999 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1004 1005 1000 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1371 1376 1367 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
The population on which our study was based is relatively large, well defined, and genetically homogenous. We were able to cover the majority of common variations in the CHEK2 gene by genotyping a relatively dense map of markers. We had detailed information about hormone-related risk factors for breast cancer that allowed us to explore gene-environment interactions. We also assessed the statistical power of our study. Until now, the power evaluations of CHEK2 genetic studies have been carried out under the assumption that the genetic risk allele is being directly tested [ 17]. This approach misleadingly overestimates power, because the susceptibility allele is rarely tested directly. Our detailed understanding of the LD pattern across CHEK2 allowed us to overcome these limitations and estimate power more accurately. To estimate power we used a method described by Chapman et al. [ 42], which assumes codominant effects at an unobserved locus (assuming 80% power, an alpha-value of 0.05, and R2 = 0.9 for the ability of haplotypes to predict the allele count at the causal locus). We estimate that our study should be able to detect a disease susceptibility locus with an odds ratio of 1.23 if its MAF is 0.5, of 1.25 if MAF = 0.35, of 1.32 if MAF = 0.15, or of 1.55 if MAF = 0.05. Therefore, given the comprehensive coverage of common genetic variants within CHEK2 by our tagSNP approach, it is unlikely that any common disease allele of at least moderate effect was missed in our study. 
###end p 46
###begin p 47
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
Selection bias could have arisen in this study, as nonparticipation was related to severe disease or death. However, CHEK2 genotype frequencies were not significantly different between cases donating tissue samples, representing more ill or deceased patients, and cases donating blood samples. This nonparticipation thus affected only the generalizability of our study. 
###end p 47
###begin p 48
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b015">15</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b021">21</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b023">23</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b011">11</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b012">12</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b022">22</xref>
###xml 303 311 303 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b022">22</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b024">24</xref>
###xml 622 630 622 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
The 1100delC variant has not previously been studied in the Swedish population. The variant is rare [ 15- 21, 23], except in a few Northern European populations such as Finland and the Netherlands, where moderate frequency of 1% or above has been observed [ 11, 12, 22]. The low population frequency of 1100delC in the Swedish population is therefore generally in line with previous data. Furthermore, the corresponding odds ratio for carriers versus noncarriers was 2.26 (95% CI, 0.99-5.15), which is also consistent with the results from other Northern European populations [ 22, 24]. Taken together, the results of our 1100delC analysis confirm that our case-control sample is representative of a Northern European population. 
###end p 48
###begin p 49
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 90 98 90 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I157T</italic>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b013">13</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b015">15</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b023">23</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b024">24</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b026">26</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b027">27</xref>
###xml 354 362 354 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 444 452 444 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b051">51</xref>
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I157T</italic>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b027">27</xref>
###xml 697 702 697 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I157T</italic>
###xml 878 880 878 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b015">15</xref>
###xml 984 986 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b052">52</xref>
###xml 1014 1019 1014 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1392 1400 1392 1400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 1411 1413 1411 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b051">51</xref>
###xml 1463 1465 1463 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b030">30</xref>
###xml 1720 1722 1720 1722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030168-b015">15</xref>
###xml 1879 1884 1879 1884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1889 1894 1889 1894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 2038 2043 2038 2043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 2145 2150 2145 2150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
A few pathogenic variants have been identified by sequencing CHEK2, examples of which are 1100delC and I157T [ 13]. Association analyses of these variants in various different populations suggest that these variants are associated with moderate risk for breast cancer and have a low population frequency [ 15, 23, 24, 26, 27]. The pathological effect of 1100delC was suggested to be due to haploinsufficiency caused by the lost function of the 1100delC truncated protein [ 51]. In contrast, by introducing a nonconservative amino acid change into the forkhead-associated domain of CHEK2, I157T may produce a dominant-negative effect by forming heterodimers with wild-type CHEK2 protein [ 27]. The I157T mutation could also have a pathological effect by producing a defective protein for binding and phosphorylating its downstream target, Cdc25A, and for binding p53 and BRCA1 [ 15]. Given the fact that CHEK2 plays a central role in the DNA damage checkpoint and apoptosis pathways [ 52], the modest effect of the CHEK2 pathogenic variants is surprising. It is however most likely due to the functional redundancy in the crucial DNA damage checkpoint pathway and thus the compensation of defect in CHEK2 function by other members of the pathway. This mechanism was suggested in a recent study showing that the normal degradation of Cdc25A is was shown to be maintained in the carriers of the 1100delC variant [ 51]. Our association study supports other reports [ 30] indicating that, besides the known pathogenic coding variants, it is unlikely that other common coding or noncoding variants play a significant role in a predisposition to breast cancer. This is consistent with the notion discussed by Cybulski et al. [ 15] that there are three classes of risk genes for breast cancer: a class of genes in which mutations are rare but confer a very high relative risk (including BRCA1 and BRCA2); a class in which variants are common but confer only modest risk (few if any such genes have been confirmed to date); and a class (including CHEK2) in which mutations are rare but associated with only modest risk. Although the idea is speculative, CHEK2 may exercise a pleiotropic effect as a central player in the DNA damage checkpoint and apoptosis pathways on other biological processes than its role in carcinogenesis, and this may provide necessary selection pressure to maintain its functional variants at a low population frequency. 
###end p 49
###begin p 50
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 194 199 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 271 276 271 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 446 452 446 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2,</italic>
###xml 465 470 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 472 481 472 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC,</italic>
To our knowledge, this is the most comprehensive evaluation of the association between the genetic variation within CHEK2 and postmenopausal breast cancer risk. However, despite the role of the CHEK2 gene in breast cancer aetiology, we conclude that common variations in CHEK2 do not affect breast cancer risk, at least not in the Swedish population. On the other hand, our study cannot exclude the possible influence of rare genetic variants in CHEK2, such as the CHEK2* 1100delC, on breast cancer risk. Investigation of such rare risk alleles in a population-based design requires a much larger sample size than the one utilized in the present study. 
###end p 50
###begin title 51
Supporting Information
###end title 51
###begin title 52
Swedish Translation of the Abstract
###end title 52
###begin p 53
(22 KB DOC)
###end p 53
###begin p 54
Click here for additional data file.
###end p 54
###begin title 55
Icelandic Translation of the Abstract
###end title 55
###begin p 56
(21 KB DOC)
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin title 58
Chinese Translation of the Abstract
###end title 58
###begin p 59
(27 KB DOC)
###end p 59
###begin p 60
Click here for additional data file.
###end p 60
###begin title 61
Association of the 19 Rare Haplotypes with Breast Cancer Risk
###end title 61
###begin p 62
(49 KB DOC)
###end p 62
###begin p 63
Click here for additional data file.
###end p 63
###begin title 64
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Common Haplotypes Reconstructed Using Six tagSNPs in CHEK2 in Relation to Breast Cancer Risk, Considering Only Cases Who Eventually Were Diagnosed with a Second Breast Cancer 
###end title 64
###begin p 65
(38 KB DOC)
###end p 65
###begin p 66
Click here for additional data file.
###end p 66
###begin title 67
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Common Haplotypes Reconstructed Using Six tagSNPs in CHEK2 in Relation to Breast Cancer Risk, by Family History 
###end title 67
###begin p 68
###xml 43 55 <span type="species:ncbi:9606">participants</span>
Family history was considered positive for participants who had at least one first-degree relative with breast cancer.
###end p 68
###begin p 69
(45 KB DOC)
###end p 69
###begin p 70
Click here for additional data file.
###end p 70
###begin title 71
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Common Haplotypes Reconstructed Using Six tagSNPs in CHEK2 in Relation to Breast Cancer Risk, Stratified by Body Mass IndexBody mass index is calculated as weight/height 2 (kg/m 2) 
###end title 71
###begin p 72
(52.5 KB DOC)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin title 74
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Common Haplotypes Reconstructed Using Six tagSNPs in CHEK2 in Relation to Breast Cancer Risk, Stratified by Age at First Childbirth 
###end title 74
###begin p 75
(51 KB DOC)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin title 77
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Common Haplotypes Reconstructed Using Six tagSNPs in CHEK2 in Relation to Breast Cancer Risk, Stratified by Duration of Use of Any Kind of Medium-Potency Oestrogens 
###end title 77
###begin p 78
(51 KB DOC)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin title 80
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Common Haplotypes Reconstructed Using Six tagSNPs in CHEK2 in Relation to Breast Cancer Risk, Stratified by Parity 
###end title 80
###begin p 81
(55 KB DOC)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin title 83
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Association between Six tagSNPs in CHEK2 and Breast Cancer Risk 
###end title 83
###begin p 84
(47 KB DOC)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin title 86
Accession Numbers
###end title 86
###begin p 87
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 36 39 <span type="species:ncbi:9606">Man</span>
The Online Mendelian Inheritance in Man ( ) accession numbers for breast cancer is MIM 114480, and for the gene CHEK2 is MIM 604373. 
###end p 87
###begin title 88
Editors' Summary
###end title 88
###begin title 89
Background.
###end title 89
###begin p 90
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 245 251 245 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2,</italic>
###xml 915 920 915 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 925 930 925 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 366 371 <span type="species:ncbi:9606">women</span>
###xml 538 543 <span type="species:ncbi:9606">women</span>
Approximately 5% of breast cancer patients have a strong familial risk for the disease. In these families, multiple family members are usually affected, often at an early age (before they are 35). Rare inherited variants in two genes, BRCA1 and BRCA2, are responsible for the high breast cancer risk in most of these "breast cancer families." Among the other 95% of women with breast cancer who are not known to have inherited one of these high-risk variants, there may still be some inherited susceptibility to the disease: about 10% of women have a "moderate" family history of breast cancer. The inherited genetic factors that are responsible for the more common but weaker susceptibility to breast cancer are so far mostly unknown. These factors could, for example, be common variants in many different genes, each of which on their own cause only a moderately raised risk (although more common variants of the BRCA1 and BRCA2 genes do not seem to be associated with breast cancer). 
###end p 90
###begin title 91
Why Was This Study Done?
###end title 91
###begin p 92
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2,</italic>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 181 190 181 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC,</italic>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 505 513 505 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 525 530 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 712 717 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 822 827 822 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
###xml 865 870 <span type="species:ncbi:9606">women</span>
###xml 939 944 <span type="species:ncbi:9606">women</span>
CHEK2 is another gene that has been associated with familial breast cancer. In some breast cancer families without mutations in BRCA1 and BRCA2, a specific variant of CHEK2 (called 1100delC, indicating a deletion at position 1100) occurred frequently in patients with breast cancer. The association between this particular CHEK2 variant and an increased risk of breast cancer was confirmed in a large study that looked at approximately 10,000 patients with breast cancer and 10,000 controls. However, the 1100delC variant of CHEK2 is rare, and scientists want to know whether more common variants of the gene were associated with breast cancer. A number of previous studies that looked at two common variants of CHEK2 had not given consistent results. This study used six common variants to predict all common variants of CHEK2 in a group of postmenopausal Swedish women and tested whether any of the six variants were associated with the women having breast cancer. 
###end p 92
###begin title 93
What Did the Researchers Do and Find?
###end title 93
###begin p 94
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 93 98 <span type="species:ncbi:9606">women</span>
###xml 186 191 <span type="species:ncbi:9606">women</span>
###xml 221 226 <span type="species:ncbi:9606">women</span>
###xml 376 381 <span type="species:ncbi:9606">women</span>
They identified the six common variants by analyzing the DNA of the CHEK2 gene in 92 Swedish women. They then compared the frequency of these common variants between approximately 1,500 women with breast cancer and 1,500 women of the same age and similar lifestyles without breast cancer. They found no association between any of the common variants and the likelihood of the women having breast cancer. 
###end p 94
###begin title 95
What Do These Findings Mean?
###end title 95
###begin p 96
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 392 400 392 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
###xml 33 38 <span type="species:ncbi:9606">women</span>
###xml 365 370 <span type="species:ncbi:9606">women</span>
###xml 794 800 <span type="species:ncbi:9606">person</span>
This study suggests that Swedish women (or those of Northern European descent who have a similar genetic inheritance) who have any of the common variants of the CHEK2 gene do not have a raised risk of getting breast cancer. However, this finding might not apply in other populations. As in previous studies, this study also found a raised risk of breast cancer for women who carried the rare 1100delC variant, but the study was too small to test whether there are other rare variants that might also predispose to breast cancer. Overall, scientists have not yet found many common gene variants that increase the risk of getting cancer. But, to test conclusively for associations between genetic variants, both common and rare, and cancer, very large studies will be needed. Understanding how a person's genetic make-up and their environment and lifestyle influence their risk for certain cancers remains a challenge. 
###end p 96
###begin title 97
Additional Information.
###end title 97
###begin p 98
Please access these Web sites via the online version of this summary at . 
###end p 98
###begin p 99
*  
###end p 99
###begin p 100
*  
###end p 100
###begin p 101
*  
###end p 101
###begin p 102
*  
###end p 102
###begin p 103
###xml 27 32 <span type="species:ncbi:9606">women</span>
###xml 741 753 <span type="species:ncbi:9606">participants</span>
We are grateful to all the women who took the time and effort to participate in this study. We are also indebted to Christer Hallden at the Department of Clinical Chemistry, Malmo University Hospital, Sweden, for overseeing the DNA isolation from the blood samples, and to our staff at the Genome Institute of Singapore: Meah Wee Yang and Ong Eng Hu Jason for genotyping; Lim Siew Lan and Irene Chen for isolating DNA from paraffin-embedded tissue; Marie Vivian Wong Tzu Yen for retrieving SNP information; and Frans Verhoeff for processing the genotyping data. Providing the indispensable foundation for this research, Anna Christensson and Boel Bissmarck obtained informed consents and coordinated the collecting of samples from the study participants.
###end p 103
###begin p 104
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. KE, JL, and SW wrote the article. KE and KH performed the statistical analyses with the assistance of JP, MMI, and AS. CB oversaw the genotyping procedures, and KE assisted with the genotyping. KE and YL selected the polymorphisms. JL and SW coordinated the study. KH, JP, KSC, ETL, PH, JL, and SW contributed to conception and design of the project and critically revised the manuscript. All authors read and approved the final manuscript. 
###end p 104
###begin title 105
References
###end title 105
###begin article-title 106
The changing global patterns of female breast cancer incidence and mortality
###end article-title 106
###begin article-title 107
###xml 56 61 <span type="species:ncbi:9606">women</span>
High constant incidence in twins and other relatives of women with breast cancer
###end article-title 107
###begin article-title 108
Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland
###end article-title 108
###begin article-title 109
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes
###end article-title 109
###begin article-title 110
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
###end article-title 110
###begin article-title 111
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
###end article-title 111
###begin article-title 112
Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1
###end article-title 112
###begin article-title 113
hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response
###end article-title 113
###begin article-title 114
###xml 64 69 <span type="species:ncbi:9606">human</span>
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
###end article-title 114
###begin article-title 115
###xml 67 72 <span type="species:ncbi:9606">human</span>
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
###end article-title 115
###begin article-title 116
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
###end article-title 116
###begin article-title 117
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer
###end article-title 117
###begin article-title 118
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
###end article-title 118
###begin article-title 119
Characterization of tumor-associated Chk2 mutations
###end article-title 119
###begin article-title 120
CHEK2 is a multiorgan cancer susceptibility gene
###end article-title 120
###begin article-title 121
###xml 97 102 <span type="species:ncbi:9606">women</span>
Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women
###end article-title 121
###begin article-title 122
CHEK2:1100delC and female breast cancer in the United States
###end article-title 122
###begin article-title 123
The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy
###end article-title 123
###begin article-title 124
The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population
###end article-title 124
###begin article-title 125
###xml 30 35 <span type="species:ncbi:9606">women</span>
Pathology of breast cancer in women with constitutional CHEK2 mutations
###end article-title 125
###begin article-title 126
Frequency of CHEK2*1100delC in New York breast cancer cases and controls
###end article-title 126
###begin article-title 127
No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors
###end article-title 127
###begin article-title 128
Breast cancer predisposing alleles in Poland
###end article-title 128
###begin article-title 129
CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies
###end article-title 129
###begin article-title 130
Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: A familial study
###end article-title 130
###begin article-title 131
Association of two mutations in the CHEK2 gene with breast cancer
###end article-title 131
###begin article-title 132
CHEK2 variant I157T may be associated with increased breast cancer risk
###end article-title 132
###begin article-title 133
Limited relevance of the CHEK2 gene in hereditary breast cancer
###end article-title 133
###begin article-title 134
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility
###end article-title 134
###begin article-title 135
Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk
###end article-title 135
###begin article-title 136
Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy
###end article-title 136
###begin article-title 137
Association of family history and other risk factors with breast cancer risk (Sweden)
###end article-title 137
###begin article-title 138
###xml 101 106 <span type="species:ncbi:9606">women</span>
The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years
###end article-title 138
###begin article-title 139
Breast cancer risk and lifetime leisure-time and occupational physical activity (Sweden)
###end article-title 139
###begin article-title 140
Brassica vegetables and breast cancer risk
###end article-title 140
###begin article-title 141
Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples
###end article-title 141
###begin article-title 142
Model-free analysis and permutation tests for allelic associations
###end article-title 142
###begin article-title 143
Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms
###end article-title 143
###begin article-title 144
Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study
###end article-title 144
###begin article-title 145
###xml 41 46 <span type="species:ncbi:9606">human</span>
The structure of haplotype blocks in the human genome
###end article-title 145
###begin article-title 146
Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: Implications for linkage-disequilibrium gene mapping
###end article-title 146
###begin article-title 147
Detecting disease associations due to linkage disequilibrium using haplotype tags: A class of tests and the determinants of statistical power
###end article-title 147
###begin article-title 148
Obtaining unbiased estimates of tagging SNP performance
###end article-title 148
###begin article-title 149
Score tests for association between traits and haplotypes when linkage phase is ambiguous
###end article-title 149
###begin article-title 150
Causal knowledge as a prerequisite for confounding evaluation: An application to birth defects epidemiology
###end article-title 150
###begin article-title 151
Fine-scale mapping of disease genes with multiple mutations via spatial clustering techniques
###end article-title 151
###begin article-title 152
###xml 61 66 <span type="species:ncbi:9606">Women</span>
Breast cancer and hormone-replacement therapy in the Million Women Study
###end article-title 152
###begin article-title 153
Reproductive factors and breast cancer
###end article-title 153
###begin article-title 154
Screening hCHK2 for mutations
###end article-title 154
###begin article-title 155
The effect of SNP marker density on the efficacy of haplotype tagging SNPs-a warning
###end article-title 155
###begin article-title 156
Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: Functional analysis in heterozygous individuals
###end article-title 156
###begin article-title 157
The Chk2 protein kinase
###end article-title 157
###begin title 158
Abbreviations
###end title 158
###begin p 159
checkpoint kinase 2
###end p 159
###begin p 160
confidence interval
###end p 160
###begin p 161
Hardy-Weinberg equilibrium
###end p 161
###begin p 162
kilobase
###end p 162
###begin p 163
linkage disequilibrium
###end p 163
###begin p 164
minor allele frequency
###end p 164
###begin p 165
odds ratio
###end p 165
###begin p 166
single nucleotide polymorphism
###end p 166
###begin p 167
haplotype-tagging single nucleotide polymorphism
###end p 167
###begin title 168
Figures and Tables
###end title 168
###begin title 169
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Exon, SNP, and LD Information for CHEK2
###end title 169
###begin p 170
Lane 1 (Chr): Physical position on chromosome 22. Lane 2 (CHEK2): Exon locations. Lane 3 (dbSNP): SNPs downloaded from dbSNP build 124. Lane 4 (Genotyped): SNPs genotyped in our study and their respective frequencies in 92 controls. Accession numbers are given for the 14 common SNPs (MAF >/= 0.03) that were in HWE, tagSNPs are marked with asterisks. LD grid: pairwise D' between the 14 common SNPs.
###end p 170
###begin p 171
Selected Characteristics of the Postmenopausal Sporadic Breast Cancer Cases and Controls Participating in the Present Study Compared to All Who Answered the Questionnaire in the Parent Study
###end p 171
###begin p 172
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Summary Data on 34 SNPs in CHEK2 and Its 5-kb Flanking Sequences Successfully Genotyped in 92 Swedish Controls 
###end p 172
###begin p 173
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Common Haplotypes Reconstructed Using 14 SNPs in CHEK2
###end p 173
###begin p 174
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Common Haplotypes Reconstructed Using Six tagSNP in CHEK2 in Relation to Breast Cancer Risk 
###end p 174
###begin p 175
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 34 42 34 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1100delC</italic>
Overall Association of the CHEK2* 1100delC Mutation with Breast Cancer Risk 
###end p 175
###begin p 176
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Citation: Einarsdottir K, Humphreys K, Bonnard C, Palmgren J, Iles MM, et al. (2006) Linkage disequilibrium mapping of CHEK2: Common variation and breast cancer risk. PLoS Med 3(6): e168. DOI: 10.1371/journal.pmed.0030168 
###end p 176
###begin p 177
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This study was supported by funding from the Agency for Science & Technology and Research of Singapore (A*STAR) and the Susan G. Komen Breast Cancer Foundation. KH, MMI, and AS were also supported by the Wallenberg Consortium North and the Swedish Foundation for Strategic Research. 
###end p 177

